DexCom, Inc. (BVMF:D1EX34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 130.65B -26.6% |
| Revenue (ttm) | 25.13B +16.2% |
| Net Income | 4.85B +73.8% |
| EPS | 12.20 +75.5% |
| Shares Out | n/a |
| PE Ratio | 26.92 |
| Forward PE | 25.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,000 |
| Average Volume | 4,219 |
| Open | 6.66 |
| Previous Close | 6.80 |
| Day's Range | 6.66 - 7.10 |
| 52-Week Range | 5.75 - 10.06 |
| Beta | 1.40 |
| RSI | 63.13 |
| Earnings Date | Apr 30, 2026 |
About DexCom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;... [Read more]
Financial Performance
In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.
Financial numbers in USD Financial StatementsNews
DexCom announces Dexcom Flex in Germany
DexCom (DXCM) announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available…
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for...
DexCom price target lowered to $80 from $100 at BofA
BofA analyst Travis Steed lowered the firm’s price target on DexCom (DXCM) to $80 from $100 and keeps a Buy rating on the shares following the company’s analyst day and…
DexCom price target lowered to $82 from $100 at Canaccord
Canaccord lowered the firm’s price target on DexCom (DXCM) to $82 from $100 and keeps a Buy rating on the shares. The firm atteended its Investor Day where management outlined…
DexCom price target lowered to $64 from $67 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on DexCom (DXCM) to $64 from $67 and keeps an Underweight rating on the shares. The company’s investor day set the…
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
DexCom NASDAQ: DXCM used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and ...
Why Is Dexcom Stock (DXCM) Soaring Today?
Dexcom ($DXCM) stock jumped about 8% on Friday, at the time of writing, as activist investor Elliott Investment Management took a stake in the maker of continuous glucose monitoring (CGM)…
Early notable gainers among liquid option names on May 15th
Notable gainers among liquid option names this morning include DexCom (DXCM) $61.10 +3.28, CH Robinson Worldwide (CHRW) $165.20 +5.42, FactSet (FDS) $206.48 +6.62, Charles Schwab (SCHW) $92.24 +2.80, ...
DexCom to collaborate with Elliott Management, name two new Board members
DexCom (DXCM) “announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the com...
Dexcom to appoint two directors, revamp board committee with Elliott
Medical device maker DexCom said on Thursday it has agreed with activist investor Elliott Investment Management to add two independent directors to the company's board and revamp a key board committ...
DexCom Transcript: Investor Day 2026
The event outlined a strategy for durable double-digit growth, driven by product innovation, expanded U.S. and international market access, and operational efficiency. Key initiatives include the G8 platform, expanded Medicare coverage, and a focus on multi-analyte sensing and preventative care.
DexCom Slides: FY 2026
DexCom has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 14, 2026.
Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic...
DexCom initiated with a Buy at Benchmark
Benchmark last night initiated coverage of DexCom (DXCM) with a Buy rating and $77 price target The company is positioned for margin expansion over the next two years as it…
DexCom initiated with a Buy at Benchmark
Benchmark initiated coverage of DexCom (DXCM) with a Buy rating.
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
3 Reasons Analysts Love DexCom
While GLP-1 agonists have grabbed investor attention for their potential as weight loss aids, these medicines also form a crucial component of a broader set of tools to address type 2 diabetes. With a...
Dexcom to Host Investor Day on May 14, 2026
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on Thursday, May 14, 2026 from 1:15 PM until approximately 3:30 PM PDT (4:15 PM – 6:30 PM EDT)....
DexCom price target lowered to $79 from $84 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on DexCom (DXCM) to $79 from $84 and keeps a Buy rating on the shares.
DexCom price target lowered to $80 from $87 at Baird
Baird lowered the firm’s price target on DexCom (DXCM) to $80 from $87 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results showing…
DexCom price target lowered to $77 from $83 at Bernstein
Bernstein lowered the firm’s price target on DexCom (DXCM) to $77 from $83 and keeps an Outperform rating on the shares. The firm notes sales grew 12% organic to $1.19B…
DexCom price target lowered to $75 from $84 at TD Cowen
TD Cowen lowered the firm’s price target on DexCom (DXCM) to $75 from $84 and keeps a Buy rating on the shares. The firm said the Q1 quarterly report checked…
DexCom price target lowered to $75 from $90 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on DexCom (DXCM) to $75 from $90 and keeps an Outperform rating on the shares.
DexCom price target lowered to $81 from $83 at Raymond James
Raymond James lowered the firm’s price target on DexCom (DXCM) to $81 from $83 and keeps a Strong Buy rating on the shares. Despite a high bar, results exceeded expectations…
Dexcom reaffirms full-year forecast after topping quarterly estimates
Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its continuous glucose monitor...